Positive patients could be good candidates for treatments with TSPY-based immunotherapeutic strategies, including reactivation of the immune responses through immunization of a therapeutic cancer vaccine [81] or treatments with antibody-drug conjugates [82] and in combination of other therapeutics [83], thereby providing effective clinical management of this prevalent liver cancer among male patients. Here, TSPY1 is linked to liver cancer.